Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mirati Therapeutics Inc receives orphan drug designation from U.S. Food & Drug Administration for Mocetinostat in Myelodysplastic Syndrome


Tuesday, 17 Jun 2014 08:00am EDT 

Mirati Therapeutics Inc:Mocetinostat, company's spectrum selective HDAC inhibitor, has been granted Orphan Drug Designation by U.S. Food & Drug Administration as treatment for myelodysplastic syndrome (MDS).Mocetinostat is being developed in Phase 2 clinical studies in combination with Vidaza as treatment for intermediate and high-risk MDS, as well as single agent treatment in patients with diffuse large B-cell lymphoma (DLBCL).Says bladder cancer targeting specific genetic mutations in histone acetylation that increase the likelihood of response in tumor cells. 

Company Quote

17.84
-0.18 -1.00%
28 Jul 2014